JW Therapeutics Secures NMPA Review for CAR-T Therapy in Mantle Cell Lymphoma
JW Therapeutics (HKG: 2126), a Chinese biopharmaceutical company, has announced that it has submitted an...
China’s Ministry of Education Launches Professional Guidelines for Healthcare Talent Training
The Ministry of Education (MoE) in China has issued a Notice outlining the “Professional Guidelines...
Jiangsu Hengrui Pharmaceuticals Advances Novel Cancer Therapies with NMPA Clinical Trial Approval
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...
Suzhou Elite Analytical Instruments Secures Over $14 Million in Initial Funding Round
Suzhou Elite Analytical Instruments Co., Ltd, a leading specialist in liquid chromatography based in China,...
Jiangsu Vcare PharmaTech Submits NDA to US FDA for Vicagrel, a P2Y12 Receptor Antagonist
Jiangsu Vcare PharmaTech Co., Ltd, a Chinese pharmaceutical company, has submitted a New Drug Application...
Allorion Therapeutics and Avenzo Seal Deal for Global Rights to CDK2 Inhibitor
China-based Allorion Therapeutics has entered into a licensing agreement with Avenzo Therapeutics Inc., granting the...
BMS’s Sotyktu, First TYK2 Inhibitor, Hits Chinese Market
US pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced the market launch of...
China’s National People’s Congress Approves Stricter Punishments for Sector-Specific Bribery
The 7th meeting of the 14th National People’s Congress Standing Committee has passed the latest...
Daiichi Sankyo and Esperion Therapeutics Amend Collaboration on Antilipidemic Drugs
Daiichi Sankyo (TYO: 4568)’s European subsidiary, a Japanese pharmaceutical company, has entered into a collaboration...
Shanghai BDgene Technology’s Thalassemia Gene Therapy BD211 Clears NMPA for Clinical Trials
Shanghai BDgene Technology Co., Ltd, a specialist in gene therapy, has received clinical trial approval...
Belief BioMed Group Initiates Clinical Study for Hemophilia A Gene Therapy BBM-H803 in China
Belief BioMed Group, a Shanghai-based gene therapy specialist, has announced the first subject dosing in...
IASO Biotherapeutics and Umoja Biopharma Join Forces for Innovative Cell and Gene Therapies Development
IASO Biotherapeutics, a China-based company, and Umoja Biopharma, a California-headquartered developer of off-the-shelf cell therapies,...
Full-Life Technologies Secures USD 63.3 Million in Financing to Boost Radiotherapeutics Pipeline and Manufacturing
Full-Life Technologies Ltd, a global radiotherapeutics company with a presence in Belgium, Germany, and China,...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approval for Abiraterone in Prostate Cancer Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received marketing approval...
ImmunoTech Biopharm Commences Patient Enrollment in Phase II Study for CAR-T-19 Injection
ImmunoTech Biopharm Ltd, a China-based specialist in chimeric antigen receptor T-cell (CAR-T) therapies (HKG: 6978),...
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer to Lead Pipeline Strategy
Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has announced the...
GenScipt Subsidiary Legend Biotech Finalizes Licensing Deal with Novartis for DLL3 CAR-T Therapies
GenScipt Biotech Corp., a China-based Contract Development and Manufacturing Organization (CDMO) (HKG: 1548), has announced...
Sino Biopharmaceutical Ltd Secures Exclusive Rights for Generic Everolimus in China
Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company based in China, has announced that...
Kexing Pharmaceutical Enters Global Licensing Agreement with Xiling Lab for Eribulin Generic
China-based Kexing Pharmaceutical (SHA: 688136) has entered into a global licensing and supply agreement with...
Bio-Thera Solutions Grants Macter International Exclusive Rights to Avzivi in Pakistan and Afghanistan
Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biopharmaceutical company, has announced a licensing and commercialization agreement...